Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| AGIOS PHARMACEUTICALS, INC.AGIO · Entity 4499 | Chief Medical Officer | June 18, 2021 | June 22, 2021 |
| Alaunos Therapeutics, Inc.TCRT · Entity 8339 | Director | June 22, 2022 | June 24, 2022 |
| Bicara Therapeutics Inc.BCAX · Entity 4673 | Director | June 09, 2026 | June 10, 2026 |
| Viridian Therapeutics, Inc.\DEMGEN · Entity 4316 | Director | May 21, 2020 | May 22, 2020 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
AGIOS PHARMACEUTICALS, INC.
Report date June 18, 2021 · Filed June 22, 2021
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common stockSEC Table I · non-derivative | Direct | 15,487 |
Ending reported balance
After 2021-06-18 transaction · row 3
3 source rows · reconciled sequenceRow 1 · 2021-06-18 · Exercise / conversion · Acquired 1,885 · Balance 17,372 F1: This exercise was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. Row 2 · 2021-06-18 · Exercise / conversion · Acquired 46,608 · Balance 63,980 F1: This exercise was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. Row 3 · 2021-06-18 · Sale · Disposed 48,493 · Balance 15,487 F2: This sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. F3: The price reported is the weighted average of the shares sold. The shares were sold at varying prices in the range of $60.00 to $60.31. The reporting person undertakes, upon request by the staff of the Securities and Exchange Commission, the issuer, or a security holder of the issuer, to provide full information regarding the number of shares sold at each separate price. |
| Stock option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $39.76 · Expires 2026-02-15 | Direct | 0 |
Reported balance
After 2021-06-18 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2021-06-18 · Exercise / conversion · Disposed 1,885 · Balance 0 F1: This exercise was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. F4: This option was granted on February 16, 2016. The shares underlying this option vest as to 25% of the underlying shares on February 16, 2017, with the remaining 75% vesting in 36 equal monthly installments thereafter. |
| Stock option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $50.40 · Expires 2027-02-20 | Direct | 992 |
Reported balance
After 2021-06-18 transaction · row 5
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 5 · 2021-06-18 · Exercise / conversion · Disposed 46,608 · Balance 992 F1: This exercise was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. F5: This option was granted on February 21, 2017. The shares underlying this option vest as to 25% of the underlying shares on February 21, 2018, with the remaining 75% vesting in 36 equal monthly installments thereafter. |
Filing footnotes · ownership attribution and instrument terms
F1: This exercise was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person.
F2: This sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person.
F3: The price reported is the weighted average of the shares sold. The shares were sold at varying prices in the range of $60.00 to $60.31. The reporting person undertakes, upon request by the staff of the Securities and Exchange Commission, the issuer, or a security holder of the issuer, to provide full information regarding the number of shares sold at each separate price.
F4: This option was granted on February 16, 2016. The shares underlying this option vest as to 25% of the underlying shares on February 16, 2017, with the remaining 75% vesting in 36 equal monthly installments thereafter.
F5: This option was granted on February 21, 2017. The shares underlying this option vest as to 25% of the underlying shares on February 21, 2018, with the remaining 75% vesting in 36 equal monthly installments thereafter.
Alaunos Therapeutics, Inc.
Report date June 22, 2022 · Filed June 24, 2022
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 44,167 |
Reported balance
After 2022-06-22 transaction · row 1
1 source rowRow 1 · 2022-06-22 · Grant · Acquired 40,000 · Balance 44,167 |
| Employee Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $0.82 · Expires 2032-06-21 | Direct | 100,000 |
Reported balance
After 2022-06-22 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2022-06-22 · Grant · Acquired 100,000 · Balance 100,000 F1: The option vests in twelve equal monthly installments beginning on July 13, 2022. |
Filing footnotes · ownership attribution and instrument terms
F1: The option vests in twelve equal monthly installments beginning on July 13, 2022.
Bicara Therapeutics Inc.
Report date June 09, 2026 · Filed June 10, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $20.56 · Expires 2036-06-09 | Direct | 19,475 |
Reported balance
After 2026-06-09 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-06-09 · Grant · Acquired 19,475 · Balance 19,475 F1: The shares underlying this stock option vest upon the earlier of (i) June 9, 2027 or (ii) the date of the next Annual Meeting of Stockholders of Bicara Therapeutics Inc., subject to the Reporting Person's continued service on such vesting date. |
Filing footnotes · ownership attribution and instrument terms
F1: The shares underlying this stock option vest upon the earlier of (i) June 9, 2027 or (ii) the date of the next Annual Meeting of Stockholders of Bicara Therapeutics Inc., subject to the Reporting Person's continued service on such vesting date.
Viridian Therapeutics, Inc.\DE
Report date May 21, 2020 · Filed May 22, 2020
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $0.63 · Expires 2030-05-20 | Direct | 24,000 |
Reported balance
After 2020-05-21 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2020-05-21 · Grant · Acquired 24,000 · Balance 24,000 F1: Automatic non-discretionary grant to the Reporting Person of a nonstatutory stock option under the Issuer's 2016 Equity Incentive Plan (the "Plan") in accordance with the Issuer's Amended and Restated Non-Employee Director Compensation Policy. One hundred percent (100%) of the shares subject to the option shall vest on the earlier of (i) the one-year anniversary of the date of grant or (ii) the date of the next annual meeting of the Issuer's stockholders following the date of grant, subject in each case to the Reporting Person's continued service on such vesting date. |
Filing footnotes · ownership attribution and instrument terms
F1: Automatic non-discretionary grant to the Reporting Person of a nonstatutory stock option under the Issuer's 2016 Equity Incentive Plan (the "Plan") in accordance with the Issuer's Amended and Restated Non-Employee Director Compensation Policy. One hundred percent (100%) of the shares subject to the option shall vest on the earlier of (i) the one-year anniversary of the date of grant or (ii) the date of the next annual meeting of the Issuer's stockholders following the date of grant, subject in each case to the Reporting Person's continued service on such vesting date.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| April 13, 2020 Filed Apr 15, 2020 20:25 UTC | AGIOS PHARMACEUTICALS, INC. AGIO · Entity 4499 | Exercise / conversionCommon stock | 5,280 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001439222-20-000028 · wf-form4_158698231920894.xml · nonDerivative · entry 1 Bowden Christopher · CIK 0001608601 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,598 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each performance share unit represents a contingent right to receive one share of the issuer's common stock. Read SEC document |
| February 24, 2020 Filed Feb 25, 2020 21:26 UTC | AGIOS PHARMACEUTICALS, INC. AGIO · Entity 4499 | Tax withholdingCommon stock | 1,596 | $48.66 | $77,661.36 |
DisclosureSEC source: 0001439222-20-000023 · wf-form4_158266595418246.xml · nonDerivative · entry 2 Bowden Christopher · CIK 0001608601 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,318 Read SEC document |
| February 22, 2020 Filed Feb 25, 2020 21:26 UTC | AGIOS PHARMACEUTICALS, INC. AGIO · Entity 4499 | Exercise / conversionRestricted stock units · Derivative | 3,333 | $0.00 | $0.00 |
DisclosureSEC source: 0001439222-20-000023 · wf-form4_158266595418246.xml · derivative · entry 3 Bowden Christopher · CIK 0001608601 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,667 Underlying: Common stock · 3,333 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of the issuer's common stock. F2 · derivative.exercise_date: The restricted stock units were granted on February 22, 2019. Beginning on February 22, 2020, the shares underlying the restricted stock units will vest in three equal annual installments. F2 · derivative.expiration_date: The restricted stock units were granted on February 22, 2019. Beginning on February 22, 2020, the shares underlying the restricted stock units will vest in three equal annual installments. Read SEC document |
| February 22, 2020 Filed Feb 25, 2020 21:26 UTC | AGIOS PHARMACEUTICALS, INC. AGIO · Entity 4499 | Exercise / conversionCommon stock | 3,333 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001439222-20-000023 · wf-form4_158266595418246.xml · nonDerivative · entry 1 Bowden Christopher · CIK 0001608601 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,914 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit represents a contingent right to receive one share of the issuer's common stock. Read SEC document |
| February 18, 2020 Filed Feb 19, 2020 21:53 UTC | AGIOS PHARMACEUTICALS, INC. AGIO · Entity 4499 | Tax withholdingCommon stock | 819 | $52.01 | $42,596.19 |
DisclosureSEC source: 0001439222-20-000018 · wf-form4_158214922111232.xml · nonDerivative · entry 2 Bowden Christopher · CIK 0001608601 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,581 Read SEC document |
| February 16, 2020 Filed Feb 19, 2020 21:53 UTC | AGIOS PHARMACEUTICALS, INC. AGIO · Entity 4499 | Exercise / conversionRestricted stock unit · Derivative | 2,750 | $0.00 | $0.00 |
DisclosureSEC source: 0001439222-20-000018 · wf-form4_158214922111232.xml · derivative · entry 5 Bowden Christopher · CIK 0001608601 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,750 Underlying: Common stock · 2,750 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of the issuer's common stock. F4 · derivative.exercise_date: The restricted stock units were granted on February 16, 2018. Beginning on February 16, 2019, the shares underlying the restricted stock units will vest in three equal annual installments. Vested shares will be delivered to the reporting person within three business days after such shares become vested. F4 · derivative.expiration_date: The restricted stock units were granted on February 16, 2018. Beginning on February 16, 2019, the shares underlying the restricted stock units will vest in three equal annual installments. Vested shares will be delivered to the reporting person within three business days after such shares become vested. Read SEC document |
| February 16, 2020 Filed Feb 19, 2020 21:53 UTC | AGIOS PHARMACEUTICALS, INC. AGIO · Entity 4499 | Exercise / conversionCommon stock | 2,750 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001439222-20-000018 · wf-form4_158214922111232.xml · nonDerivative · entry 1 Bowden Christopher · CIK 0001608601 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,400 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit represents a contingent right to receive one share of the issuer's common stock. Read SEC document |
| February 14, 2020 Filed Feb 19, 2020 21:53 UTC | AGIOS PHARMACEUTICALS, INC. AGIO · Entity 4499 | GrantStock option (right to buy) · Derivative | 45,000 | $0.00 Strike: $51.51 | $0.00 |
DisclosureSEC source: 0001439222-20-000018 · wf-form4_158214922111232.xml · derivative · entry 4 Bowden Christopher · CIK 0001608601 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 45,000 Underlying: Common stock · 45,000 shares Expires 2030-02-14 F3 · derivative.exercise_date: This option was granted on February 14, 2020. The shares underlying this option vest as to 25% of the underlying shares on February 14, 2021, with the remaining 75% vesting in 36 equal monthly installments thereafter. Read SEC document |
| February 14, 2020 Filed Feb 19, 2020 21:53 UTC | AGIOS PHARMACEUTICALS, INC. AGIO · Entity 4499 | GrantRestricted stock units · Derivative | 12,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001439222-20-000018 · wf-form4_158214922111232.xml · derivative · entry 3 Bowden Christopher · CIK 0001608601 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,000 Underlying: Common stock · 12,000 shares Expires not disclosed F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of the issuer's common stock. F2 · derivative.exercise_date: The restricted stock units were granted on February 14, 2020. Beginning on February, 2021, the shares underlying the restricted stock units will vest in three equal annual installments. F2 · derivative.expiration_date: The restricted stock units were granted on February 14, 2020. Beginning on February, 2021, the shares underlying the restricted stock units will vest in three equal annual installments. Read SEC document |
| February 13, 2020 Filed Feb 18, 2020 21:05 UTC | AGIOS PHARMACEUTICALS, INC. AGIO · Entity 4499 | Exercise / conversionStock option (right to buy) · Derivative | 7,100 | $0.00 Strike: $35.16 | $0.00 |
DisclosureSEC source: 0001439222-20-000008 · wf-form4_158205991627413.xml · derivative · entry 3 Bowden Christopher · CIK 0001608601 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 19,306 Underlying: Common stock · 7,100 shares Expires 2024-05-30 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This exercise was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. F4 · derivative.exercise_date: This option was granted on May 31, 2014. The shares underlying this option vest as to 25% of the underlying shares on May 13, 2015, with the remaining 75% vesting in 36 equal monthly installments thereafter. Read SEC document |
| February 13, 2020 Filed Feb 18, 2020 21:05 UTC | AGIOS PHARMACEUTICALS, INC. AGIO · Entity 4499 | SaleCommon stock | 7,100 | $50.16 | $356,111.86 |
DisclosureSEC source: 0001439222-20-000008 · wf-form4_158205991627413.xml · nonDerivative · entry 2 Bowden Christopher · CIK 0001608601 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,650 F2 · kind: This sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. F3 · price: The price reported is the weighted average of the shares sold. The shares were sold at varying prices in the range of $50.00 to $50.82. The reporting person undertakes, upon request by the staff of the Securities and Exchange Commission, the issuer, or a security holder of the issuer, to provide full information regarding the number of shares sold at each separate price. Read SEC document |
| February 13, 2020 Filed Feb 18, 2020 21:05 UTC | AGIOS PHARMACEUTICALS, INC. AGIO · Entity 4499 | Exercise / conversionCommon stock | 7,100 | $35.16 | $249,636.00 |
DisclosureSEC source: 0001439222-20-000008 · wf-form4_158205991627413.xml · nonDerivative · entry 1 Bowden Christopher · CIK 0001608601 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,750 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This exercise was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. Read SEC document |
| February 11, 2020 Filed Feb 13, 2020 21:21 UTC | AGIOS PHARMACEUTICALS, INC. AGIO · Entity 4499 | Exercise / conversionStock option (right to buy) · Derivative | 621 | $0.00 Strike: $35.16 | $0.00 |
DisclosureSEC source: 0001439222-20-000006 · wf-form4_158162886617100.xml · derivative · entry 3 Bowden Christopher · CIK 0001608601 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 26,406 Underlying: Common stock · 621 shares Expires 2024-05-30 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This exercise was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. F4 · derivative.exercise_date: This option was granted on May 31, 2014. The shares underlying this option vest as to 25% of the underlying shares on May 13, 2015, with the remaining 75% vesting in 36 equal monthly installments thereafter. Read SEC document |
| February 11, 2020 Filed Feb 13, 2020 21:21 UTC | AGIOS PHARMACEUTICALS, INC. AGIO · Entity 4499 | SaleCommon stock | 621 | $50.02 | $31,063.23 |
DisclosureSEC source: 0001439222-20-000006 · wf-form4_158162886617100.xml · nonDerivative · entry 2 Bowden Christopher · CIK 0001608601 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,650 F2 · kind: This sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. F3 · price: The price reported is the weighted average of the shares sold. The shares were sold at varying prices in the range of $50.00 to $50.06. The reporting person undertakes, upon request by the staff of the Securities and Exchange Commission, the issuer, or a security holder of the issuer, to provide full information regarding the number of shares sold at each separate price. Read SEC document |
| February 11, 2020 Filed Feb 13, 2020 21:21 UTC | AGIOS PHARMACEUTICALS, INC. AGIO · Entity 4499 | Exercise / conversionCommon stock | 621 | $35.16 | $21,834.36 |
DisclosureSEC source: 0001439222-20-000006 · wf-form4_158162886617100.xml · nonDerivative · entry 1 Bowden Christopher · CIK 0001608601 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,271 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This exercise was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. Read SEC document |
| February 05, 2020 Filed Feb 6, 2020 21:52 UTC | AGIOS PHARMACEUTICALS, INC. AGIO · Entity 4499 | Exercise / conversionStock option (right to buy) · Derivative | 35,447 | $0.00 Strike: $35.16 | $0.00 |
DisclosureSEC source: 0001439222-20-000005 · wf-form4_158102593034853.xml · derivative · entry 6 Bowden Christopher · CIK 0001608601 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 27,027 Underlying: Common stock · 35,447 shares Expires 2024-05-30 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This exercise was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. F6 · derivative.exercise_date: This option was granted on May 31, 2014. The shares underlying this option vest as to 25% of the underlying shares on May 13, 2015, with the remaining 75% vesting in 36 equal monthly installments thereafter. Read SEC document |
| February 05, 2020 Filed Feb 6, 2020 21:52 UTC | AGIOS PHARMACEUTICALS, INC. AGIO · Entity 4499 | Exercise / conversionCommon stock | 35,447 | $35.16 | $1,246,316.52 |
DisclosureSEC source: 0001439222-20-000005 · wf-form4_158102593034853.xml · nonDerivative · entry 3 Bowden Christopher · CIK 0001608601 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 37,097 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This exercise was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. Read SEC document |
| February 04, 2020 Filed Feb 6, 2020 21:52 UTC | AGIOS PHARMACEUTICALS, INC. AGIO · Entity 4499 | Exercise / conversionStock option (right to buy) · Derivative | 8,526 | $0.00 Strike: $35.16 | $0.00 |
DisclosureSEC source: 0001439222-20-000005 · wf-form4_158102593034853.xml · derivative · entry 5 Bowden Christopher · CIK 0001608601 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 62,474 Underlying: Common stock · 8,526 shares Expires 2024-05-30 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This exercise was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. F6 · derivative.exercise_date: This option was granted on May 31, 2014. The shares underlying this option vest as to 25% of the underlying shares on May 13, 2015, with the remaining 75% vesting in 36 equal monthly installments thereafter. Read SEC document |
| February 04, 2020 Filed Feb 6, 2020 21:52 UTC | AGIOS PHARMACEUTICALS, INC. AGIO · Entity 4499 | SaleCommon stock | 35,447 | $50.10 | $1,776,025.85 |
DisclosureSEC source: 0001439222-20-000005 · wf-form4_158102593034853.xml · nonDerivative · entry 4 Bowden Christopher · CIK 0001608601 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,650 F3 · kind: This sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. F5 · price: The price reported is the weighted average of the shares sold. The shares were sold at varying prices in the range of $50.00 to $50.46. The reporting person undertakes, upon request by the staff of the Securities and Exchange Commission, the issuer, or a security holder of the issuer, to provide full information regarding the number of shares sold at each separate price. Read SEC document |
| February 04, 2020 Filed Feb 6, 2020 21:52 UTC | AGIOS PHARMACEUTICALS, INC. AGIO · Entity 4499 | SaleCommon stock | 14,191 | $50.03 | $709,962.96 |
DisclosureSEC source: 0001439222-20-000005 · wf-form4_158102593034853.xml · nonDerivative · entry 2 Bowden Christopher · CIK 0001608601 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,650 F3 · kind: This sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. F4 · price: The price reported is the weighted average of the shares sold. The shares were sold at varying prices in the range of $50.00 to $50.23. The reporting person undertakes, upon request by the staff of the Securities and Exchange Commission, the issuer, or a security holder of the issuer, to provide full information regarding the number of shares sold at each separate price. Read SEC document |
| February 04, 2020 Filed Feb 6, 2020 21:52 UTC | AGIOS PHARMACEUTICALS, INC. AGIO · Entity 4499 | Exercise / conversionCommon stock | 8,526 | $35.16 | $299,774.16 |
DisclosureSEC source: 0001439222-20-000005 · wf-form4_158102593034853.xml · nonDerivative · entry 1 Bowden Christopher · CIK 0001608601 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,841 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This exercise was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. F2 · balance_after: Includes 77 shares purchased through the Company's employee stock purchase plan. Read SEC document |
| December 31, 2019 Filed Jan 3, 2020 22:02 UTC | Alaunos Therapeutics, Inc. ZIOP · Entity 8339 | GrantStock Option (right to buy) · Derivative | 50,562 | $0.00 Strike: $4.72 | $0.00 |
DisclosureSEC source: 0001209191-20-001164 · doc4.xml · derivative · entry 1 Bowden Christopher · CIK 0001608601 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 50,562 Underlying: Common Stock · 50,562 shares Expires 2029-12-31 F1 · derivative.exercise_date: 100% of the shares subject to the option vest on December 31, 2020, subject to Reporting Person's continuous service with the Issuer through such date. Read SEC document |
| October 25, 2019 Filed Oct 30, 2019 01:09 UTC | Alaunos Therapeutics, Inc. ZIOP · Entity 8339 | GrantStock Option (right to buy) · Derivative | 94,031 | $0.00 Strike: $4.26 | $0.00 |
DisclosureSEC source: 0001209191-19-054401 · doc4.xml · derivative · entry 1 Bowden Christopher · CIK 0001608601 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 94,031 Underlying: Common Stock · 94,031 shares Expires 2029-10-25 F1 · derivative.exercise_date: 100% of the shares subject to the option vest on October 8, 2021, subject to Reporting Person's continuous service with the Issuer through such date. Read SEC document |
| June 19, 2019 Filed Jun 21, 2019 21:12 UTC | Viridian Therapeutics, Inc.\DE MGEN · Entity 4316 | GrantStock Option (right to buy) · Derivative | 12,000 | $0.00 Strike: $2.36 | $0.00 |
DisclosureSEC source: 0001209191-19-038556 · doc4.xml · derivative · entry 1 Bowden Christopher · CIK 0001608601 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,000 Underlying: Common Stock · 12,000 shares Expires 2029-06-18 F1 · derivative.exercise_date: Automatic non-discretionary grant to the Reporting Person of a nonstatutory stock option under the Issuer's 2016 Equity Incentive Plan (the "Plan") in accordance with the Issuer's Amended and Restated Non-Employee Director Compensation Policy. One hundred percent (100%) of the shares subject to the option shall vest on the earlier of (i) the one-year anniversary of the date of grant or (ii) the date of the next annual meeting of the Issuer's stockholders following the date of grant, subject in each case to the Reporting Person's continued service on such vesting date. Read SEC document |
| April 01, 2019 Filed Apr 3, 2019 20:12 UTC | AGIOS PHARMACEUTICALS, INC. AGIO · Entity 4499 | Exercise / conversionStock option (right to buy) · Derivative | 10,000 | $0.00 Strike: $35.16 | $0.00 |
DisclosureSEC source: 0001209191-19-023072 · doc4.xml · derivative · entry 6 Bowden Christopher · CIK 0001608601 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 71,000 Underlying: Common stock · 10,000 shares Expires 2024-05-30 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This exercise was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. F6 · derivative.exercise_date: This option was granted on May 31, 2014. The shares underlying this option vest as to 25% of the underlying shares on May 13, 2015, with the remaining 75% vesting in 36 equal monthly installments thereafter. Read SEC document |
| April 01, 2019 Filed Apr 3, 2019 20:12 UTC | AGIOS PHARMACEUTICALS, INC. AGIO · Entity 4499 | SaleCommon stock | 100 | $68.72 | $6,872.00 |
DisclosureSEC source: 0001209191-19-023072 · doc4.xml · nonDerivative · entry 5 Bowden Christopher · CIK 0001608601 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,238 F2 · kind: This sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. Read SEC document |
| April 01, 2019 Filed Apr 3, 2019 20:12 UTC | AGIOS PHARMACEUTICALS, INC. AGIO · Entity 4499 | SaleCommon stock | 1,500 | $68.09 | $102,135.00 |
DisclosureSEC source: 0001209191-19-023072 · doc4.xml · nonDerivative · entry 4 Bowden Christopher · CIK 0001608601 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,338 F2 · kind: This sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. F5 · price: The price reported is the weighted average of the shares sold. The shares were sold at varying prices in the range of $67.71 to $68.55. The reporting person undertakes, upon request by the staff of the Securities and Exchange Commission, the issuer, or a security holder of the issuer, to provide full information regarding the number of shares sold at each separate price. Read SEC document |
| April 01, 2019 Filed Apr 3, 2019 20:12 UTC | AGIOS PHARMACEUTICALS, INC. AGIO · Entity 4499 | SaleCommon stock | 2,546 | $66.85 | $170,200.10 |
DisclosureSEC source: 0001209191-19-023072 · doc4.xml · nonDerivative · entry 3 Bowden Christopher · CIK 0001608601 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,838 F2 · kind: This sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. F4 · price: The price reported is the weighted average of the shares sold. The shares were sold at varying prices in the range of $66.50 to $67.07. The reporting person undertakes, upon request by the staff of the Securities and Exchange Commission, the issuer, or a security holder of the issuer, to provide full information regarding the number of shares sold at each separate price. Read SEC document |
| April 01, 2019 Filed Apr 3, 2019 20:12 UTC | AGIOS PHARMACEUTICALS, INC. AGIO · Entity 4499 | SaleCommon stock | 5,854 | $66.03 | $386,539.62 |
DisclosureSEC source: 0001209191-19-023072 · doc4.xml · nonDerivative · entry 2 Bowden Christopher · CIK 0001608601 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,384 F2 · kind: This sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. F3 · price: The price reported is the weighted average of the shares sold. The shares were sold at varying prices in the range of $65.50 to $66.49. The reporting person undertakes, upon request by the staff of the Securities and Exchange Commission, the issuer, or a security holder of the issuer, to provide full information regarding the number of shares sold at each separate price. Read SEC document |
| April 01, 2019 Filed Apr 3, 2019 20:12 UTC | AGIOS PHARMACEUTICALS, INC. AGIO · Entity 4499 | Exercise / conversionCommon stock | 10,000 | $35.16 | $351,600.00 |
DisclosureSEC source: 0001209191-19-023072 · doc4.xml · nonDerivative · entry 1 Bowden Christopher · CIK 0001608601 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 17,238 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This exercise was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. Read SEC document |
| March 15, 2019 Filed Mar 19, 2019 20:25 UTC | AGIOS PHARMACEUTICALS, INC. AGIO · Entity 4499 | Exercise / conversionStock option (right to buy) · Derivative | 10,000 | $0.00 Strike: $35.16 | $0.00 |
DisclosureSEC source: 0001209191-19-020288 · doc4.xml · derivative · entry 4 Bowden Christopher · CIK 0001608601 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 81,000 Underlying: Common stock · 10,000 shares Expires 2024-05-30 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This exercise was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. F6 · derivative.exercise_date: This option was granted on May 31, 2014. The shares underlying this option vest as to 25% of the underlying shares on May 13, 2015, with the remaining 75% vesting in 36 equal monthly installments thereafter. Read SEC document |
| March 15, 2019 Filed Mar 19, 2019 20:25 UTC | AGIOS PHARMACEUTICALS, INC. AGIO · Entity 4499 | SaleCommon stock | 1,300 | $64.64 | $84,032.00 |
DisclosureSEC source: 0001209191-19-020288 · doc4.xml · nonDerivative · entry 3 Bowden Christopher · CIK 0001608601 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,238 F3 · kind: This sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. F5 · price: The price reported is the weighted average of the shares sold. The shares were sold at varying prices in the range of $64.59 to $64.68. The reporting person undertakes, upon request by the staff of the Securities and Exchange Commission, the issuer, or a security holder of the issuer, to provide full information regarding the number of shares sold at each separate price. Read SEC document |
| March 15, 2019 Filed Mar 19, 2019 20:25 UTC | AGIOS PHARMACEUTICALS, INC. AGIO · Entity 4499 | SaleCommon stock | 8,700 | $64.09 | $557,583.00 |
DisclosureSEC source: 0001209191-19-020288 · doc4.xml · nonDerivative · entry 2 Bowden Christopher · CIK 0001608601 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,538 F3 · kind: This sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. F4 · price: The price reported is the weighted average of the shares sold. The shares were sold at varying prices in the range of $63.54 to $64.46. The reporting person undertakes, upon request by the staff of the Securities and Exchange Commission, the issuer, or a security holder of the issuer, to provide full information regarding the number of shares sold at each separate price. Read SEC document |
| March 15, 2019 Filed Mar 19, 2019 20:25 UTC | AGIOS PHARMACEUTICALS, INC. AGIO · Entity 4499 | Exercise / conversionCommon stock | 10,000 | $35.16 | $351,600.00 |
DisclosureSEC source: 0001209191-19-020288 · doc4.xml · nonDerivative · entry 1 Bowden Christopher · CIK 0001608601 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 17,238 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This exercise was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. F2 · balance_after: Includes 43 shares purchased through the Company's employee stock purchase plan. Read SEC document |
| February 22, 2019 Filed Feb 26, 2019 21:25 UTC | AGIOS PHARMACEUTICALS, INC. AGIO · Entity 4499 | GrantRestricted stock units · Derivative | 10,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-19-013531 · doc4.xml · derivative · entry 2 Bowden Christopher · CIK 0001608601 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,000 Underlying: Common stock · 10,000 shares Expires not disclosed F2 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of the issuer's common stock. F3 · derivative.exercise_date: The restricted stock units were granted on February 22, 2019. Beginning on February 22, 2020, the shares underlying the restricted stock units will vest in three equal annual installments. F3 · derivative.expiration_date: The restricted stock units were granted on February 22, 2019. Beginning on February 22, 2020, the shares underlying the restricted stock units will vest in three equal annual installments. Read SEC document |
| February 22, 2019 Filed Feb 26, 2019 21:25 UTC | AGIOS PHARMACEUTICALS, INC. AGIO · Entity 4499 | GrantStock option (right to buy) · Derivative | 40,000 | $0.00 Strike: $58.86 | $0.00 |
DisclosureSEC source: 0001209191-19-013531 · doc4.xml · derivative · entry 1 Bowden Christopher · CIK 0001608601 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 40,000 Underlying: Common stock · 40,000 shares Expires 2029-02-22 F1 · derivative.exercise_date: This option was granted on February 22, 2019. The shares underlying this option vest as to 25% of the underlying shares on February 22, 2020, with the remaining 75% vesting in 36 equal monthly installments thereafter. Read SEC document |
| February 19, 2019 Filed Feb 20, 2019 21:04 UTC | AGIOS PHARMACEUTICALS, INC. AGIO · Entity 4499 | Tax withholdingCommon stock | 818 | $58.03 | $47,468.54 |
DisclosureSEC source: 0001209191-19-011489 · doc4.xml · nonDerivative · entry 2 Bowden Christopher · CIK 0001608601 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,195 Read SEC document |
| February 16, 2019 Filed Feb 20, 2019 21:04 UTC | AGIOS PHARMACEUTICALS, INC. AGIO · Entity 4499 | Exercise / conversionRestricted stock unit · Derivative | 2,750 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-19-011489 · doc4.xml · derivative · entry 3 Bowden Christopher · CIK 0001608601 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,500 Underlying: Common stock · 2,750 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of the issuer's common stock. F3 · derivative.exercise_date: The restricted stock units were granted on February 16, 2018. Beginning on February 16, 2019, the shares underlying the restricted stock units will vest in three equal annual installments. Vested shares will be delivered to the reporting person within three business days after such shares become vested. F3 · derivative.expiration_date: The restricted stock units were granted on February 16, 2018. Beginning on February 16, 2019, the shares underlying the restricted stock units will vest in three equal annual installments. Vested shares will be delivered to the reporting person within three business days after such shares become vested. Read SEC document |
| February 16, 2019 Filed Feb 20, 2019 21:04 UTC | AGIOS PHARMACEUTICALS, INC. AGIO · Entity 4499 | Exercise / conversionCommon stock | 2,750 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-19-011489 · doc4.xml · nonDerivative · entry 1 Bowden Christopher · CIK 0001608601 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,013 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit represents a contingent right to receive one share of the issuer's common stock. F2 · balance_after: Includes 34 shares purchased through the Company's employee stock purchase plan. Read SEC document |
| January 22, 2019 Filed Jan 23, 2019 21:12 UTC | AGIOS PHARMACEUTICALS, INC. AGIO · Entity 4499 | Tax withholdingCommon stock | 1,960 | $52.82 | $103,527.20 |
DisclosureSEC source: 0001209191-19-004950 · doc4.xml · nonDerivative · entry 2 Bowden Christopher · CIK 0001608601 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,229 Read SEC document |
| January 20, 2019 Filed Jan 23, 2019 21:12 UTC | AGIOS PHARMACEUTICALS, INC. AGIO · Entity 4499 | Exercise / conversionPerformance share unit · Derivative | 6,265 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-19-004950 · doc4.xml · derivative · entry 3 Bowden Christopher · CIK 0001608601 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common stock · 6,265 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each performance share unit represents a contingent right to receive one share of the issuer's common stock. F2 · derivative.exercise_date: The performance share units were originally granted on December 21, 2015. The performance share units vest in full six months after the achievement of performance milestone. Performance milestone was achieved on July 20, 2018, and the performance share will vest in full on January 20, 2019. Vested shares will be delivered to the reporting person within three business days after such shares become vested. F2 · derivative.expiration_date: The performance share units were originally granted on December 21, 2015. The performance share units vest in full six months after the achievement of performance milestone. Performance milestone was achieved on July 20, 2018, and the performance share will vest in full on January 20, 2019. Vested shares will be delivered to the reporting person within three business days after such shares become vested. Read SEC document |
| January 20, 2019 Filed Jan 23, 2019 21:12 UTC | AGIOS PHARMACEUTICALS, INC. AGIO · Entity 4499 | Exercise / conversionCommon stock | 6,265 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-19-004950 · doc4.xml · nonDerivative · entry 1 Bowden Christopher · CIK 0001608601 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,189 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each performance share unit represents a contingent right to receive one share of the issuer's common stock. Read SEC document |
| August 30, 2018 Filed Aug 31, 2018 20:02 UTC | AGIOS PHARMACEUTICALS, INC. AGIO · Entity 4499 | Exercise / conversionStock option (right to buy) · Derivative | 1,700 | $0.00 Strike: $35.16 | $0.00 |
DisclosureSEC source: 0001209191-18-049065 · doc4.xml · derivative · entry 6 Bowden Christopher · CIK 0001608601 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 91,000 Underlying: Common stock · 1,700 shares Expires 2024-05-30 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This exercise was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. F4 · derivative.exercise_date: This option was granted on May 31, 2014. The shares underlying this option vest as to 25% of the underlying shares on May 13, 2015, with the remaining 75% vesting in 36 equal monthly installments thereafter. Read SEC document |
| August 30, 2018 Filed Aug 31, 2018 20:02 UTC | AGIOS PHARMACEUTICALS, INC. AGIO · Entity 4499 | SaleCommon stock | 1,700 | $80.03 | $136,051.00 |
DisclosureSEC source: 0001209191-18-049065 · doc4.xml · nonDerivative · entry 4 Bowden Christopher · CIK 0001608601 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 924 F2 · kind: This sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. F3 · price: The price reported is the weighted average of the shares sold. The shares were sold at varying prices in the range of $80.00 to $80.28. The reporting person undertakes, upon request by the staff of the Securities and Exchange Commission, the issuer, or a security holder of the issuer, to provide full information regarding the number of shares sold at each separate price. Read SEC document |
| August 30, 2018 Filed Aug 31, 2018 20:02 UTC | AGIOS PHARMACEUTICALS, INC. AGIO · Entity 4499 | Exercise / conversionCommon stock | 1,700 | $35.16 | $59,772.00 |
DisclosureSEC source: 0001209191-18-049065 · doc4.xml · nonDerivative · entry 3 Bowden Christopher · CIK 0001608601 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,624 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This exercise was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. Read SEC document |
| August 29, 2018 Filed Aug 31, 2018 20:02 UTC | AGIOS PHARMACEUTICALS, INC. AGIO · Entity 4499 | Exercise / conversionStock option (right to buy) · Derivative | 300 | $0.00 Strike: $35.16 | $0.00 |
DisclosureSEC source: 0001209191-18-049065 · doc4.xml · derivative · entry 5 Bowden Christopher · CIK 0001608601 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 92,700 Underlying: Common stock · 300 shares Expires 2024-05-30 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This exercise was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. F4 · derivative.exercise_date: This option was granted on May 31, 2014. The shares underlying this option vest as to 25% of the underlying shares on May 13, 2015, with the remaining 75% vesting in 36 equal monthly installments thereafter. Read SEC document |
| August 29, 2018 Filed Aug 31, 2018 20:02 UTC | AGIOS PHARMACEUTICALS, INC. AGIO · Entity 4499 | SaleCommon stock | 300 | $80.00 | $24,000.00 |
DisclosureSEC source: 0001209191-18-049065 · doc4.xml · nonDerivative · entry 2 Bowden Christopher · CIK 0001608601 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 924 F2 · kind: This sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. Read SEC document |
| August 29, 2018 Filed Aug 31, 2018 20:02 UTC | AGIOS PHARMACEUTICALS, INC. AGIO · Entity 4499 | Exercise / conversionCommon stock | 300 | $35.16 | $10,548.00 |
DisclosureSEC source: 0001209191-18-049065 · doc4.xml · nonDerivative · entry 1 Bowden Christopher · CIK 0001608601 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,224 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This exercise was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. Read SEC document |
| July 20, 2018 Filed Jul 24, 2018 20:32 UTC | AGIOS PHARMACEUTICALS, INC. AGIO · Entity 4499 | GrantPerformance share units · Derivative | 6,265 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-18-043729 · doc4.xml · derivative · entry 1 Bowden Christopher · CIK 0001608601 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,265 Underlying: Common Stock · 6,265 shares Expires not disclosed F1 · derivative.exercise_price: Each performance share unit represents a contingent right to receive one share of the issuer's common stock. F2 · derivative.exercise_date: The performance share units were originally granted on December 21, 2015. The performance share units vest in full six months after the achievement of a performance milestone. The performance milestone was achieved on July 20, 2018, and the performance share units will vest in full on January 20, 2019. Vested shares will be delivered to the reporting person within three business days after such shares become vested. F2 · derivative.expiration_date: The performance share units were originally granted on December 21, 2015. The performance share units vest in full six months after the achievement of a performance milestone. The performance milestone was achieved on July 20, 2018, and the performance share units will vest in full on January 20, 2019. Vested shares will be delivered to the reporting person within three business days after such shares become vested. Read SEC document |
| July 10, 2018 Filed Jul 12, 2018 20:14 UTC | AGIOS PHARMACEUTICALS, INC. AGIO · Entity 4499 | Exercise / conversionStock option (right to buy) · Derivative | 2,000 | $0.00 Strike: $35.16 | $0.00 |
DisclosureSEC source: 0001209191-18-042453 · doc4.xml · derivative · entry 4 Bowden Christopher · CIK 0001608601 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 93,000 Underlying: Common stock · 2,000 shares Expires 2024-05-30 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This exercise was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. F6 · derivative.exercise_date: This option was granted on May 31, 2014. The shares underlying this option vest as to 25% of the underlying shares on May 13, 2015, with the remaining 75% vesting in 36 equal monthly installments thereafter. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.